Details of the Drug Combination

General Information of Drug Combination (ID: DC8M9Z3)

Drug Combination Name
Prednisolone Tacrolimus
Indication
Disease Entry Status REF
Sjogren Syndrome With Other Organ Involvement Phase 2 [1]
Component Drugs Prednisolone   DMQ8FR2 Tacrolimus   DMZ7XNQ
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Prednisolone
Disease Entry ICD 11 Status REF
Acute adrenal insufficiency N.A. Approved [2]
Acute asthma CA23 Approved [2]
Addison disease 5A74.0 Approved [2]
Allergic rhinitis CA08.0 Approved [2]
Angioedema 4A00.15 Approved [2]
Aspiration pneumonitis N.A. Approved [2]
Autoimmune haemolytic anaemia 3A20 Approved [2]
Blepharoconjunctivitis N.A. Approved [2]
Bursitis N.A. Approved [2]
Cerebral edema 8D60.1 Approved [2]
Chronic graft versus host disease N.A. Approved [2]
Congenital adrenal hyperplasia 5A71.01 Approved [2]
Corneal abrasion NA06.4 Approved [2]
Corneal ulcer 9A76 Approved [2]
Crohn disease DD70 Approved [2]
Dacryocystitis N.A. Approved [2]
Demodex blepharitis 1G07 Approved [2]
Dermatitis herpetiformis EB44 Approved [2]
Diamond-Blackfan anemia N.A. Approved [2]
Disorder of orbital region N.A. Approved [2]
Epicondylitis N.A. Approved [2]
Erythema multiforme N.A. Approved [2]
Exanthem N.A. Approved [2]
Fever MG26 Approved [2]
Granuloma annulare N.A. Approved [2]
Hypersensitivity pneumonitis N.A. Approved [2]
Inflammatory bowel disease DD72 Approved [2]
Ischemia-reperfusion injury DB98.B Approved [2]
Keratitis N.A. Approved [2]
Leukemia N.A. Approved [2]
Lupus nephritis 4A40.0Y Approved [2]
Microscopic polyangiitis N.A. Approved [2]
Miliary tuberculosis N.A. Approved [2]
Mycosis fungoides 2B01 Approved [2]
Myeloproliferative neoplasm 2A20 Approved [2]
Pneumocystis pneumonia CA40.20 Approved [2]
Polymyalgia rheumatica N.A. Approved [2]
Primary cutaneous T-cell lymphoma N.A. Approved [2]
Psoriasis EA90 Approved [2]
Psoriatic arthritis FA21 Approved [2]
Rheumatic heart disease N.A. Approved [2]
Rosacea ED90.0 Approved [2]
Sarcoidosis 4B20.5 Approved [2]
Serum sickness N.A. Approved [2]
Severe asthma CA23 Approved [2]
Skin disease EA00-EM0Z Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Sympathetic ophthalmia N.A. Approved [2]
Systemic lupus erythematosus 4A40.0 Approved [2]
Ulcerative colitis DD71 Approved [2]
Multiple sclerosis 8A40 Phase 3 [4]
Acquired thrombocytopenia N.A. Investigative [2]
Asthma CA23 Investigative [2]
Beta-thalassemia major N.A. Investigative [2]
Classic Hodgkin lymphoma N.A. Investigative [2]
Follicular lymphoma 2A80 Investigative [2]
Iridocyclitis N.A. Investigative [2]
Sjogren syndrome 4A43.20 Investigative [2]
Synovitis N.A. Investigative [2]
Uveitis 9A96.Z Investigative [2]
Prednisolone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Modulator [10]
------------------------------------------------------------------------------------
Prednisolone Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]
------------------------------------------------------------------------------------
Prednisolone Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [13]
------------------------------------------------------------------------------------
Prednisolone Interacts with 121 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [14]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Increases Expression [7]
Phospholipid phosphatase 3 (PLPP3) OTSSF7BK PLPP3_HUMAN Decreases Expression [7]
Interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) OTPGHZB9 IFIT3_HUMAN Decreases Expression [7]
Calmegin (CLGN) OTEWVFQV CLGN_HUMAN Decreases Expression [7]
D-3-phosphoglycerate dehydrogenase (PHGDH) OT1LMRTG SERA_HUMAN Decreases Expression [7]
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2) OT0KMIYQ RIPK2_HUMAN Decreases Expression [7]
Gasdermin-E (GSDME) OT1ZWY32 GSDME_HUMAN Decreases Expression [7]
Toll-like receptor 2 (TLR2) OTGO5P4R TLR2_HUMAN Decreases Expression [7]
CCN family member 5 (CCN5) OTADU8JJ CCN5_HUMAN Increases Expression [7]
Antiviral innate immune response receptor RIG-I (RIGI) OTFIIC43 RIGI_HUMAN Decreases Expression [7]
2'-5'-oligoadenylate synthase 1 (OAS1) OT8ZLOCY OAS1_HUMAN Decreases Expression [7]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [7]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Decreases Expression [7]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Decreases Expression [7]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [7]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Increases Expression [7]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Decreases Expression [7]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Decreases Expression [7]
Steryl-sulfatase (STS) OTXTJQPC STS_HUMAN Increases Expression [7]
Neuromedin-B (NMB) OT4NLN6H NMB_HUMAN Decreases Expression [7]
Stromelysin-2 (MMP10) OTJDWW8Q MMP10_HUMAN Decreases Expression [7]
Growth-regulated alpha protein (CXCL1) OT3WCTZV GROA_HUMAN Decreases Expression [7]
Interferon alpha-inducible protein 6 (IFI6) OTWOOAM4 IFI6_HUMAN Decreases Expression [7]
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) OTXOQDSG IFIT1_HUMAN Decreases Expression [7]
Interleukin-1 receptor antagonist protein (IL1RN) OT308CBE IL1RA_HUMAN Decreases Expression [7]
C-X-C motif chemokine 2 (CXCL2) OTEJCYMY CXCL2_HUMAN Decreases Expression [7]
C-X-C motif chemokine 3 (CXCL3) OTSL94KH CXCL3_HUMAN Decreases Expression [7]
Interferon-induced GTP-binding protein Mx1 (MX1) OT6X8G5T MX1_HUMAN Decreases Expression [7]
Fibulin-1 (FBLN1) OT5MHHOP FBLN1_HUMAN Increases Expression [7]
Atypical chemokine receptor 3 (ACKR3) OTA6GA4F ACKR3_HUMAN Decreases Expression [7]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1) OTO7FJA9 DHI1_HUMAN Decreases Expression [7]
Adenosine receptor A2a (ADORA2A) OTVRBZ0I AA2AR_HUMAN Decreases Expression [7]
CCN family member 2 (CCN2) OTC39NSU CCN2_HUMAN Increases Expression [7]
Myristoylated alanine-rich C-kinase substrate (MARCKS) OT7N056G MARCS_HUMAN Decreases Expression [7]
Guanylate-binding protein 1 (GBP1) OTUM7RPJ GBP1_HUMAN Decreases Expression [7]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [7]
Macrophage metalloelastase (MMP12) OT9Z7LHM MMP12_HUMAN Decreases Expression [7]
Interferon alpha-inducible protein 27, mitochondrial (IFI27) OTI2XGIT IFI27_HUMAN Decreases Expression [7]
Regulator of G-protein signaling 4 (RGS4) OTG94HHL RGS4_HUMAN Decreases Expression [7]
Prolargin (PRELP) OT9EEBUJ PRELP_HUMAN Increases Expression [7]
Spermine synthase (SMS) OT8JYKNH SPSY_HUMAN Decreases Expression [7]
C-X-C chemokine receptor type 4 (CXCR4) OTUFSBX2 CXCR4_HUMAN Decreases Expression [7]
C-C motif chemokine 20 (CCL20) OTUCJY4N CCL20_HUMAN Decreases Expression [7]
DNA-binding protein inhibitor ID-3 (ID3) OTUULW5Z ID3_HUMAN Increases Expression [7]
Tumor necrosis factor alpha-induced protein 2 (TNFAIP2) OTRZH80H TNAP2_HUMAN Decreases Expression [7]
Aldehyde oxidase (AOX1) OT2FZP6H AOXA_HUMAN Increases Expression [7]
Bone marrow stromal antigen 2 (BST2) OTU4LCJV BST2_HUMAN Decreases Expression [7]
EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) OTZVUOOB FBLN3_HUMAN Increases Expression [7]
Neuronal membrane glycoprotein M6-b (GPM6B) OT8Q1582 GPM6B_HUMAN Increases Expression [7]
Laminin subunit beta-3 (LAMB3) OTFPU6W8 LAMB3_HUMAN Decreases Expression [7]
Nidogen-2 (NID2) OTHC33FF NID2_HUMAN Increases Expression [7]
Signal transducer and activator of transcription 4 (STAT4) OTAK3VFR STAT4_HUMAN Decreases Expression [7]
2'-5'-oligoadenylate synthase-like protein (OASL) OTZ05YRP OASL_HUMAN Decreases Expression [7]
Bcl-2-related protein A1 (BCL2A1) OTWRYSNA B2LA1_HUMAN Decreases Expression [7]
Lymphocyte antigen 6E (LY6E) OTMG16BZ LY6E_HUMAN Decreases Expression [7]
Interferon-induced protein 44-like (IFI44L) OTXKORJP IF44L_HUMAN Decreases Expression [7]
Olfactomedin-like protein 2B (OLFML2B) OTDNJFR4 OLM2B_HUMAN Increases Expression [7]
E3 ubiquitin-protein ligase RNF19B (RNF19B) OTYCWKBP RN19B_HUMAN Decreases Expression [7]
Amphoterin-induced protein 2 (AMIGO2) OTPAIT1O AMGO2_HUMAN Decreases Expression [7]
Probable E3 ubiquitin-protein ligase HERC6 (HERC6) OT7G9PQE HERC6_HUMAN Decreases Expression [7]
Equilibrative nucleobase transporter 1 (SLC43A3) OTR60ZLA S43A3_HUMAN Decreases Expression [7]
Interferon-induced protein 44 (IFI44) OTOKSZVA IFI44_HUMAN Decreases Expression [7]
S-adenosylmethionine-dependent nucleotide dehydratase RSAD2 (RSAD2) OTCA9WCM RSAD2_HUMAN Decreases Expression [7]
Nuclear receptor subfamily 4 group A member 3 (NR4A3) OTPBE9R1 NR4A3_HUMAN Decreases Expression [7]
Type II iodothyronine deiodinase (DIO2) OTGPNSLH IOD2_HUMAN Increases Expression [7]
Interferon regulatory factor 7 (IRF7) OTC1A2PQ IRF7_HUMAN Decreases Expression [7]
Interferon-stimulated gene 20 kDa protein (ISG20) OTCWRJJW ISG20_HUMAN Decreases Expression [7]
Interferon-induced helicase C domain-containing protein 1 (IFIH1) OTZA2AHA IFIH1_HUMAN Decreases Expression [7]
Anthrax toxin receptor 1 (ANTXR1) OT5W1GPC ANTR1_HUMAN Increases Expression [7]
Interleukin-23 subunit alpha (IL23A) OTYO99HC IL23A_HUMAN Decreases Expression [7]
NADH dehydrogenase 1 alpha subcomplex subunit 4-like 2 (NDUFA4L2) OTK0PG7R NUA4L_HUMAN Decreases Expression [7]
Large neutral amino acids transporter small subunit 2 (SLC7A8) OT8XXVO8 LAT2_HUMAN Increases Expression [7]
E3 ISG15--protein ligase HERC5 (HERC5) OTZ5PR39 HERC5_HUMAN Decreases Expression [7]
Paired immunoglobulin-like type 2 receptor alpha (PILRA) OTBE0PLF PILRA_HUMAN Decreases Expression [7]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [7]
Cytochrome P450 2S1 (CYP2S1) OTKHX4RF CP2S1_HUMAN Decreases Expression [15]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Increases Expression [8]
Inactive phospholipase C-like protein 1 (PLCL1) OTJL2C79 PLCL1_HUMAN Increases Expression [8]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Increases Expression [8]
Programmed cell death protein 4 (PDCD4) OTZ6NXUX PDCD4_HUMAN Increases Expression [8]
Kelch-like protein 24 (KLHL24) OTWZSX5C KLH24_HUMAN Increases Expression [8]
Protein FAM200C (FAM200C) OTZOXUEK F200C_HUMAN Increases Expression [8]
Arrestin domain-containing protein 3 (ARRDC3) OTAKW7R9 ARRD3_HUMAN Increases Expression [8]
Sulfiredoxin-1 (SRXN1) OTYDBO4L SRXN1_HUMAN Increases Expression [8]
Cysteine-rich motor neuron 1 protein (CRIM1) OTTZNV6Y CRIM1_HUMAN Increases Expression [8]
SLAM family member 5 (CD84) OTAY5B0F SLAF5_HUMAN Increases Expression [8]
PDZ and LIM domain protein 1 (PDLIM1) OT4EGCPG PDLI1_HUMAN Increases Expression [16]
Basic helix-loop-helix ARNT-like protein 1 (BMAL1) OTMI12L2 BMAL1_HUMAN Increases Expression [17]
Period circadian protein homolog 2 (PER2) OTU2B1DJ PER2_HUMAN Decreases Expression [17]
Period circadian protein homolog 1 (PER1) OTVQF3WX PER1_HUMAN Increases Expression [17]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Expression [18]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Expression [19]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [16]
Albumin (ALB) OTVMM513 ALBU_HUMAN Increases Expression [20]
Serotransferrin (TF) OT41PEMS TRFE_HUMAN Increases Expression [20]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Increases Activity [21]
Insulin-like growth factor I (IGF1) OTIIZR61 IGF1_HUMAN Decreases Response To Substance [22]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Decreases Expression [23]
Interleukin-5 (IL5) OTAFPSCO IL5_HUMAN Decreases Expression [23]
Mineralocorticoid receptor (NR3C2) OT0F2V2Z MCR_HUMAN Increases Activity [21]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [16]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Increases Expression [9]
C-C motif chemokine 4 (CCL4) OT6B8P25 CCL4_HUMAN Increases Expression [9]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [9]
Ganglioside GM2 activator (GM2A) OTIRWZC0 SAP3_HUMAN Increases Expression [16]
Nuclear receptor subfamily 1 group D member 1 (NR1D1) OTJ38PTB NR1D1_HUMAN Decreases Expression [17]
C-X-C chemokine receptor type 2 (CXCR2) OTISGW7L CXCR2_HUMAN Decreases Expression [24]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Increases Expression [16]
Growth/differentiation factor 5 (GDF5) OTOV8S81 GDF5_HUMAN Decreases Expression [25]
Tissue factor pathway inhibitor 2 (TFPI2) OTZCRWOR TFPI2_HUMAN Decreases Expression [16]
Transcription factor SOX-9 (SOX9) OTVDJFGN SOX9_HUMAN Decreases Expression [16]
D site-binding protein (DBP) OTE0W7LN DBP_HUMAN Decreases Expression [17]
Cryptochrome-1 (CRY1) OTTGAJT0 CRY1_HUMAN Decreases Expression [17]
Mucin-16 (MUC16) OTHPPE67 MUC16_HUMAN Decreases Expression [26]
Lymphocyte antigen 96 (LY96) OTN4HXA2 LY96_HUMAN Decreases Expression [16]
DNA topoisomerase 1 (TOP1) OT51O0CF TOP1_HUMAN Increases ADR [27]
Histone-lysine N-methyltransferase 2A (KMT2A) OT9GLJI6 KMT2A_HUMAN Decreases Response To Substance [28]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Increases Metabolism [29]
Mothers against decapentaplegic homolog 1 (SMAD1) OTQSHR25 SMAD1_HUMAN Increases ADR [27]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Increases ADR [27]
------------------------------------------------------------------------------------
⏷ Show the Full List of 121 DOT(s)
Indication(s) of Tacrolimus
Disease Entry ICD 11 Status REF
Graft-versus-host disease 4B24 Approved [5]
Hepatosplenic T-cell lymphoma N.A. Approved [5]
Kidney transplant rejection NE84 Approved [5]
Large granular lymphocytic leukemia 2A90.1 Approved [5]
Leukemia N.A. Approved [5]
Lupus nephritis 4A40.0Y Approved [5]
MALT lymphoma N.A. Approved [5]
Myeloproliferative neoplasm 2A20 Approved [5]
Nodal marginal zone lymphoma 2A85.0 Approved [5]
Organ transplant rejection NE84 Approved [6]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [5]
Recurrent adult burkitt lymphoma 2A85.6 Approved [5]
Small intestine lymphoma N.A. Approved [5]
Splenic marginal zone lymphoma N.A. Approved [5]
Testicular lymphoma N.A. Approved [5]
Ocular allergy 4A81 Phase 3 [6]
Classic Hodgkin lymphoma N.A. Investigative [5]
Tacrolimus Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Calcineurin (PPP3CA) TTA4LDE PP2BA_HUMAN Inhibitor [32]
------------------------------------------------------------------------------------
Tacrolimus Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [33]
------------------------------------------------------------------------------------
Tacrolimus Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [34]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [35]
NADPH-cytochrome P450 reductase (CPR) DE3N2FM NCPR_HUMAN Metabolism [36]
Ribosomal 23S RNA methyltransferase Erm (erm) DEW6V07 A0A5N1AHF6_CORAY Metabolism [37]
Ribosomal 23S RNA methyltransferase Erm (erm) DEA65D8 A0A381KDL2_CORJE Metabolism [37]
------------------------------------------------------------------------------------
Tacrolimus Interacts with 49 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Methylation [38]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Decreases Methylation [38]
NADPH--cytochrome P450 reductase (POR) OTVIDOCH NCPR_HUMAN Affects Response To Substance [39]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Response To Substance [40]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Increases Expression [41]
Cytochrome b-245 light chain (CYBA) OT16N9ZO CY24A_HUMAN Increases Expression [41]
Nitric oxide synthase 3 (NOS3) OTLDT7NR NOS3_HUMAN Increases Expression [41]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [42]
Natural cytotoxicity triggering receptor 3 (NCR3) OT20M764 NCTR3_HUMAN Increases Expression [43]
Hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) OTCYYCAC HGS_HUMAN Increases Expression [31]
Rho guanine nucleotide exchange factor 11 (ARHGEF11) OTDOMEH6 ARHGB_HUMAN Increases Expression [31]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [44]
Actin-related protein 2/3 complex subunit 5 (ARPC5) OTFNMMDL ARPC5_HUMAN Increases Expression [31]
G2/mitotic-specific cyclin-B2 (CCNB2) OTIEXTDK CCNB2_HUMAN Decreases Expression [44]
Zinc finger protein SNAI1 (SNAI1) OTDPYAMC SNAI1_HUMAN Increases Expression [30]
Insulin (INS) OTZ85PDU INS_HUMAN Decreases Expression [45]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Secretion [46]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Decreases Expression [47]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [48]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [49]
Fibronectin (FN1) OTB5ZN4Q FINC_HUMAN Increases Expression [49]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Decreases Expression [47]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Decreases Expression [47]
Interleukin-5 (IL5) OTAFPSCO IL5_HUMAN Decreases Expression [50]
Interleukin-3 (IL3) OT0CQ35N IL3_HUMAN Decreases Expression [47]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [51]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Decreases Expression [30]
C-C motif chemokine 5 (CCL5) OTSCA5CK CCL5_HUMAN Decreases Expression [50]
Ras-related protein Rab-4A (RAB4A) OT7BL9WW RAB4A_HUMAN Increases Expression [31]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Decreases Degradation [46]
T-lymphocyte activation antigen CD80 (CD80) OTJBLUQE CD80_HUMAN Decreases Expression [52]
T-lymphocyte activation antigen CD86 (CD86) OTJCSBPC CD86_HUMAN Decreases Expression [52]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Cleavage [53]
Troponin T, cardiac muscle (TNNT2) OT80NN7R TNNT2_HUMAN Increases Expression [54]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Decreases Secretion [55]
Glycogen synthase kinase-3 alpha (GSK3A) OT0F6DWV GSK3A_HUMAN Increases Phosphorylation [30]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [30]
Eotaxin (CCL11) OT3BIFPK CCL11_HUMAN Decreases Expression [50]
C-C chemokine receptor type 3 (CCR3) OT6GBUFA CCR3_HUMAN Decreases Expression [50]
LIM domain kinase 1 (LIMK1) OTFZ8MZ0 LIMK1_HUMAN Increases Expression [31]
Interleukin-2 (IL2) OTGI4NSA IL2_HUMAN Decreases Expression [47]
Neutrophil gelatinase-associated lipocalin (LCN2) OTSB42BR NGAL_HUMAN Increases Expression [49]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [53]
Lethal(2) giant larvae protein homolog 1 (LLGL1) OTAIQSXZ L2GL1_HUMAN Increases Expression [31]
Calcineurin subunit B type 1 (PPP3R1) OTGQNFJQ CANB1_HUMAN Increases ADR [27]
Catalase (CAT) OTHEBX9R CATA_HUMAN Decreases Response To Substance [56]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Response To Substance [56]
Peroxisome proliferator-activated receptor alpha (PPARA) OTK095PP PPARA_HUMAN Affects Response To Substance [39]
Cytochrome P450 3A7 (CYP3A7) OTTCDHHM CP3A7_HUMAN Decreases Methylation [38]
------------------------------------------------------------------------------------
⏷ Show the Full List of 49 DOT(s)

References

1 ClinicalTrials.gov (NCT05694130) Tacrolimus Plus Glucocorticoid for Severe Thrombocytopenia in SS
2 Prednisolone FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2866).
5 Tacrolimus FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6784).
7 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
8 Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
9 Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
10 Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
11 The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol. 2002 Oct;175(1):251-60.
12 Inter-individual difference determinant of prednisolone pharmacokinetics for Japanese renal transplant recipients in the maintenance stage. Xenobiotica. 2009 Dec;39(12):939-45.
13 Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. J Pharmacokinet Biopharm. 1999 Feb;27(1):1-21.
14 Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
15 CYP2S1 is negatively regulated by corticosteroids in human cell lines. Toxicol Lett. 2012 Feb 25;209(1):30-4.
16 Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
17 Chronic treatment with prednisolone represses the circadian oscillation of clock gene expression in mouse peripheral tissues. Mol Endocrinol. 2006 Mar;20(3):573-83. doi: 10.1210/me.2005-0165. Epub 2005 Nov 3.
18 Steroid therapy and urinary transforming growth factor-beta1 in IgA nephropathy. Am J Kidney Dis. 2001 Dec;38(6):1191-8. doi: 10.1053/ajkd.2001.29209.
19 Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail. 2009 May;11(5):463-71. doi: 10.1093/eurjhf/hfp028. Epub 2009 Feb 20.
20 Prednisolone can increase glomerular permeability to proteins in nephrotic syndrome. Kidney Int. 1988 Jun;33(6):1169-74. doi: 10.1038/ki.1988.126.
21 Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004 Sep;151(3):397-406. doi: 10.1530/eje.0.1510397.
22 Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. Ann Rheum Dis. 2006 Mar;65(3):301-5. doi: 10.1136/ard.2005.040816. Epub 2005 Aug 3.
23 JTP-27536 [(+)-1,3-dihydroxy-2-hydroxymethylpropyl-2-ammonium 2-[(R)-3-cyclo-hexyl-1-phenylpropyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylate monohydrate], a novel inhibitor of immunoglobulins and interleukin-5 with anti-inflammatory properties in mouse allergic dermatitis model. J Pharmacol Exp Ther. 2005 Jul;314(1):293-301. doi: 10.1124/jpet.104.080846. Epub 2005 Apr 8.
24 CXCR2 Expression on neutrophils is upregulated during the relapsing phase of ocular Behcet disease. Curr Eye Res. 2005 Mar;30(3):195-203. doi: 10.1080/02713680490904331.
25 Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium. Scand J Rheumatol. 2008 Nov-Dec;37(6):401-9. doi: 10.1080/03009740802120010.
26 Dermatomyositis associated with membranous nephropathy in a 43-year-old female. Am J Nephrol. 2002 Jul-Aug;22(4):385-8. doi: 10.1159/000065233.
27 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
28 In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia. 2004 Mar;18(3):521-9. doi: 10.1038/sj.leu.2403253.
29 Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.
30 GSK3, snail, and adhesion molecule regulation by cyclosporine A in renal tubular cells. Toxicol Sci. 2012 Jun;127(2):425-37. doi: 10.1093/toxsci/kfs108. Epub 2012 Mar 12.
31 Calcineurin is an important factor involved in glucose uptake in human adipocytes. Mol Cell Biochem. 2018 Aug;445(1-2):157-168. doi: 10.1007/s11010-017-3261-0. Epub 2018 Jan 27.
32 Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
33 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
34 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
35 Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol. 2007 Aug;21(4):427-35.
36 Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics. 2017 Sep;27(9):337-346.
37 High frequency of macrolide resistance mechanisms in clinical isolates of Corynebacterium species. Microb Drug Resist. 2010 Dec;16(4):273-7.
38 Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem. 2005 Aug;51(8):1374-81.
39 Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor- are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. Pharmacogenet Genomics. 2013 Dec;23(12):649-57. doi: 10.1097/FPC.0000000000000001.
40 Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation. 2002 Aug 27;74(4):571-2. doi: 10.1097/00007890-200208270-00024.
41 Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol. 2002 Oct;40(4):625-31.
42 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
43 Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen. Biol Blood Marrow Transplant. 2011 Feb;17(2):205-13. doi: 10.1016/j.bbmt.2010.08.014. Epub 2010 Aug 22.
44 CyclinB2 and BIRC5 genes as surrogate biomarkers for neurite outgrowth in SH-SY5Y subclonal cells. Neuropharmacology. 2006 Jun;50(8):1041-7. doi: 10.1016/j.neuropharm.2006.02.004. Epub 2006 Mar 30.
45 Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells. Am J Transplant. 2007 Apr;7(4):1021-6. doi: 10.1111/j.1600-6143.2006.01728.x.
46 FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor-kappaB. Br J Dermatol. 2005 Oct;153(4):725-32. doi: 10.1111/j.1365-2133.2005.06779.x.
47 Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). Int Immunopharmacol. 2001 Jun;1(6):1219-26. doi: 10.1016/s1567-5769(01)00059-5.
48 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
49 Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation. Arch Toxicol. 2018 Apr;92(4):1539-1550. doi: 10.1007/s00204-018-2158-3. Epub 2018 Jan 23.
50 Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. Br J Dermatol. 2005 Jun;152(6):1173-81. doi: 10.1111/j.1365-2133.2005.06474.x.
51 A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol. 2016 Apr;27(4):1015-28. doi: 10.1681/ASN.2015010060. Epub 2015 Aug 10.
52 Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol. 2004 Jul;114(1):137-43. doi: 10.1016/j.jaci.2004.03.021.
53 Immunosuppressive calcineurin inhibitor cyclosporine A?induces proapoptotic endoplasmic reticulum stress in renal tubular cells. J Biol Chem. 2022 Mar;298(3):101589. doi: 10.1016/j.jbc.2022.101589. Epub 2022 Jan 14.
54 Multicenter prospective investigation on cardiovascular adverse effects of tacrolimus in kidney transplantations. Cardiovasc Drugs Ther. 2003 Mar;17(2):141-9. doi: 10.1023/a:1025339819051.
55 Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol. 2001 Nov;108(5):839-46. doi: 10.1067/mai.2001.118796.
56 Hydrogen peroxide mediates FK506-induced cytotoxicity in renal cells. Kidney Int. 2004 Jan;65(1):139-47. doi: 10.1111/j.1523-1755.2004.00380.x.